The pharmaceutical industry in Europe and the United States announced that more data would be made public

Recently, the pharmaceutical industry in Europe and the United States expressed their willingness to release a large number of research data held by the company At a press conference, two of the world's leading trading institutions said they would "significantly increase the amount of information available to researchers, patients and the public" But advocates and researchers of the campaign for more clinical trial data say the move is small and too late   The European Pharmaceutical Industry Alliance (EFPIA) and the American pharmaceutical research and Manufacturers Association (PhRMA) jointly said that they would open patient level clinical trial information to researchers They also promised to provide detailed "clinical research reports," which some scientists have repeatedly asked for   At present, in the face of more and more outspoken requirements of doctors and scientists, medical research is in a very critical period Advocates say it is crucial to read the data to prevent the pharmaceutical industry from hiding results that are not good for its products   Some researchers hope that pharmaceutical companies will make all the clinical trial data public, while others believe that after the independent commission's verification, researchers should have the right to obtain the information in the relevant trials   For pharma and EFPIA's move, the industry has been accused of not doing enough Carl heneghan, director of the evidence based medicine center at Oxford University and founder of all trials campaign, which promotes more open clinical trials, said the industry announcement was "shrouded in warnings" that if a company believes that it is not in its interest to disclose information, it may allow the company to refuse information requests without disclosing it   In any case, Christopher Viehbacher, President of EFPIA and CEO of Sanofi, said: "information about their clinical research, collaboration with academic researchers will be published on a regular basis, and their trial data will be shared on public websites." (Yang Jihua)